Treatment patterns and outcomes in patients with metastatic colorectal cancer based on analysis of a health insurance claim database
Not Applicable
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000039590
- Lead Sponsor
- the 22nd Century Cutting-Edge Medical Information Technology Organization
- Brief Summary
As this study used a retrospective cohort design, we cannot make definite conclusions. However, in terms of TTF, BEV seemed to be a favorable option compared with ramucirumab and aflubercept when combined with FOLFIRI, and IRIS might be a preferred option compared to FOLFIRI when combined with bevacizumab for patients who failed to respond to fluoropyrimidine, oxaliplatin, and bevacizumab.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3136
Inclusion Criteria
Not provided
Exclusion Criteria
Nothing in particular
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method